With Wyeth, Pfizer To Become Second-largest Multinational Pharma In India
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Pfizer's mega buyout of Wyeth for $68 billion is set to further strengthen the Indian businesses of the world's largest drug maker with additional focus on tapping the domestic formulations business and enhancing clinical trials
You may also be interested in...
Pfizer To Become Largest Pharma In Japan After Wyeth Merger
TOKYO - Pfizer Japan says upon Pfizer's expected merger with Wyeth later this year, it will become the largest pharmaceutical company in Japan, surpassing Takeda Pharmaceutical
Pfizer To Become Largest Pharma In Japan After Wyeth Merger
Together, the two pharmas’ domestic drug sales top Takeda’s reining 6.1 percent market share.
Pfizer To Become Largest Pharma In Japan After Wyeth Merger
TOKYO - Pfizer Japan says upon Pfizer's expected merger with Wyeth later this year, it will become the largest pharmaceutical company in Japan, surpassing Takeda Pharmaceutical
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports